 The study is designed to establish safety, tolerability and immunogenicity of rVSVΔG-ZEBOV-GP BPSC1001, an Ebola Virus Vaccine candidate recombinant vesicular stomatitis virus VSV expressing the envelope glycoprotein of Ebola Virus Zaire, investigated at three different dose levels in 30 healthy adults in Germany. This study is part of the WHO led VEBCON consortium that is aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP BPSC1001 vaccine candidate to allow optimized rapid decisions on dose and safety. 